RAYNHAM, Mass., Dec. 7, 2017 /PRNewswire/ -- OMNIlife science, Inc. ("OMNI"), a privately-held, established medical technology company targeting the $15 billion global hip and knee replacement device market, reported today that, after more than 100 cases, the positive clinical value of the OMNIBotics® Active Spacer is coming into sharper focus. The multi-center U.S. study is evaluating this breakthrough technology that combines the accuracy of robotic-assisted bone cutting with active soft tissue management. The study currently involves five sites with additional sites to be added over the next several months.
The results from the initial four U.S. sites reflect the positive outcomes experienced in the Australian pilot program underway since March. "The excellent experience that has been seen in the US parallels the experience we have seen over the first 6 months," said Dr. Brett Fritsch, MD, FRACS, in Sydney. "Our patients all seem to be doing very well. They are achieving a good range of motion and excellent mobility at the early stage of their recovery."
"Our theory is that less ligament surgery will create less pain and swelling after surgery, faster recovery and better motion," said Dr. Jeffrey Lawrence, MD of Viroqua, WI. "We can now balance the knee in real time, while also decreasing the amount of surgery required."
The OMNIBotics® Active Spacer is currently the only system enabling the surgeon to predictively balance the ligaments through dynamic real-time feedback across the entire range of motion and deliver the accuracy of computer calculated, robotic-assisted bone cutting. Engineered to optimize OMNI's Apex™ Knee replacement implants, the system provides a customized procedure designed to maximize patient outcomes.
"With many studies indicating that a significant percentage of knee replacement patients are not fully satisfied with the results, the OMNIBotics Active Spacer technology provides the surgeon with a quantitative tool to plan bone cuts to address the resulting ligament balance," said Christian Joly, Vice President of Robotics at OMNI. "We believe that this advanced robotic device is helping increase surgeon confidence, improve consistency, and reduce the number of soft tissue releases by creating a customized patient-specific procedure."
OMNI is a privately held company with a proprietary robotic platform, OMNIBotics®, which allows surgeons to conduct patient-specific total knee surgery designed to enhance patient satisfaction and reduce hospital costs. In addition, OMNI designs, engineers, manufactures and distributes a wide range of proprietary hip and knee implants and is focused on providing cutting edge technologies to transform outcomes in joint replacement surgery and enhance a surgeon's ability to help patients live active and pain-free lives. For more information about OMNI, please visit www.omnils.com.
FORWARD LOOKING STATEMENTS
Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., including its plans specific to OMNIBotics systems, as well as statements using the terms "plans," "believes" or similar expressions are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management's current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI's markets, decrease in the demand for OMNI's products, delays in OMNI's product research and development cycles, decreases in the use of OMNI's principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI's current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI's current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI's sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI's products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward-looking statements after the date of this press release.
Cindy Holloway, Director of Marketing Communications
Phone: (508) 824-2444
View original content with multimedia:http://www.prnewswire.com/news-releases/omnilife-science-inc-reports-successful-completion-of-first-100-omnibotics-active-spacer-robotic-assisted-total-knee-replacement-procedures-300568422.html
SOURCE OMNIlife science, Inc.